Arecor Therape Regulatory News (AREC)

Arecor Therapeutics plc

("Arecor" or the "Group")

NOTICE OF PRELIMINARY RESULTS

Cambridge, UK, 29 March 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, will announce its preliminary results for the year ended 31 December 2021 on Monday 25 April 2022.

Sarah Howell, Chief Executive Officer, and Susan Lowther, Chief Financial Officer, will host an in-person briefing for analysts at 11:00am BST on the day of the results at the offices of Panmure Gordon, One New Change, London, EC4M 9AF. There will also be a live webcast and conference call with a Q&A session.

For more details or to attend the briefing, please contact arecor@consilium-comms.com

-ENDS-

For more information, please contact:

Notes to Editors

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.

For further details please see our website, www.arecor.com